10-Year Data Show Continuous Ocrelizumab Reduces Disability Progression in MS

The OPERA I and II trials followed 1,656 patients with relapsing multiple sclerosis for up to 10 years, comparing continuous ocrelizumab treatment with a 2-year delayed start (initial interferon beta-1a followed by ocrelizumab). The trials reported that continuous ocrelizumab reduced the hazard of confirmed disability progression by 24% and reduced progression to an EDSS score of 6.0 by 43% compared with delayed initiation, while relapse rates and adverse event rates, including serious infections, did not increase over the extension period.

Most relevant for: Patients with relapsing multiple sclerosis being considered for early versus delayed initiation of high-efficacy disease-modifying therapy.

Summary written by an AI model from the source text and dated by the source's publication date. Check the original before acting on it. How MedFollow selects and summarizes updates.

Informational only. Not medical advice. Not a substitute for clinical judgment. Always consult current guidelines and your own clinical judgment.